Therapeutic Research in Alzheimer’s Disease: What Is New?

by | Mar 2, 2026 | Health

Spread the love
Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.
Medscape News Europe

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments